DermTech Competitors

DermTech (NASDAQ:DMTK) and Burning Rock Biotech (NASDAQ:BNR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares DermTech and Burning Rock Biotech's revenue, earnings per share (EPS) and valuation.

Burning Rock Biotech has lower revenue, but higher earnings than DermTech.

Insider and Institutional Ownership

51.4% of DermTech shares are held by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are held by institutional investors. 16.5% of DermTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares DermTech and Burning Rock Biotech's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for DermTech and Burning Rock Biotech, as reported by MarketBeat.com.

DermTech currently has a consensus price target of $50.25, indicating a potential downside of 5.15%. Burning Rock Biotech has a consensus price target of $32.30, indicating a potential downside of 10.53%. Given DermTech's higher probable upside, equities analysts plainly believe DermTech is more favorable than Burning Rock Biotech.

Summary

DermTech beats Burning Rock Biotech on 5 of the 8 factors compared between the two stocks.

DermTech (NASDAQ:DMTK) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for DermTech and CareDx, as reported by MarketBeat.com.

DermTech currently has a consensus price target of $50.25, indicating a potential downside of 5.15%. CareDx has a consensus price target of $75.8333, indicating a potential upside of 14.29%. Given CareDx's higher probable upside, analysts plainly believe CareDx is more favorable than DermTech.

Earnings & Valuation

This table compares DermTech and CareDx's revenue, earnings per share (EPS) and valuation.

DermTech has higher earnings, but lower revenue than CareDx. CareDx is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

51.4% of DermTech shares are held by institutional investors. 16.5% of DermTech shares are held by insiders. Comparatively, 3.1% of CareDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

DermTech has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, CareDx has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Profitability

This table compares DermTech and CareDx's net margins, return on equity and return on assets.

Veracyte (NASDAQ:VCYT) and DermTech (NASDAQ:DMTK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Veracyte and DermTech, as reported by MarketBeat.com.

Veracyte presently has a consensus price target of $59.2857, indicating a potential upside of 26.38%. DermTech has a consensus price target of $50.25, indicating a potential downside of 5.15%. Given Veracyte's higher probable upside, research analysts clearly believe Veracyte is more favorable than DermTech.

Earnings and Valuation

This table compares Veracyte and DermTech's revenue, earnings per share (EPS) and valuation.

Veracyte has higher revenue and earnings than DermTech. Veracyte is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

51.4% of DermTech shares are owned by institutional investors. 8.3% of Veracyte shares are owned by insiders. Comparatively, 16.5% of DermTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Veracyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, DermTech has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Profitability

This table compares Veracyte and DermTech's net margins, return on equity and return on assets.

Summary

Veracyte beats DermTech on 7 of the 13 factors compared between the two stocks.

Fulgent Genetics (NASDAQ:FLGT) and DermTech (NASDAQ:DMTK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Fulgent Genetics and DermTech, as reported by MarketBeat.com.

Fulgent Genetics presently has a consensus price target of $73.40, indicating a potential downside of 14.18%. DermTech has a consensus price target of $50.25, indicating a potential downside of 5.15%. Given DermTech's stronger consensus rating and higher probable upside, analysts clearly believe DermTech is more favorable than Fulgent Genetics.

Earnings and Valuation

This table compares Fulgent Genetics and DermTech's revenue, earnings per share (EPS) and valuation.

Fulgent Genetics has higher revenue and earnings than DermTech. DermTech is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

33.4% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 51.4% of DermTech shares are owned by institutional investors. 45.0% of Fulgent Genetics shares are owned by insiders. Comparatively, 16.5% of DermTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Fulgent Genetics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, DermTech has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Profitability

This table compares Fulgent Genetics and DermTech's net margins, return on equity and return on assets.

Summary

Fulgent Genetics beats DermTech on 9 of the 14 factors compared between the two stocks.

Genetron (NASDAQ:GTH) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Genetron and DermTech's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Genetron and DermTech's revenue, earnings per share (EPS) and valuation.

DermTech has lower revenue, but higher earnings than Genetron.

Analyst Ratings

This is a summary of current ratings and target prices for Genetron and DermTech, as reported by MarketBeat.com.

Genetron presently has a consensus price target of $19.50, indicating a potential downside of 10.06%. DermTech has a consensus price target of $50.25, indicating a potential downside of 5.15%. Given DermTech's higher probable upside, analysts clearly believe DermTech is more favorable than Genetron.

Institutional and Insider Ownership

19.6% of Genetron shares are owned by institutional investors. Comparatively, 51.4% of DermTech shares are owned by institutional investors. 16.5% of DermTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

DermTech beats Genetron on 6 of the 10 factors compared between the two stocks.

Castle Biosciences (NASDAQ:CSTL) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Castle Biosciences and DermTech's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Castle Biosciences and DermTech's revenue, earnings per share (EPS) and valuation.

Castle Biosciences has higher revenue and earnings than DermTech. Castle Biosciences is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Castle Biosciences and DermTech, as reported by MarketBeat.

Castle Biosciences presently has a consensus price target of $73.80, indicating a potential upside of 8.10%. DermTech has a consensus price target of $50.25, indicating a potential downside of 5.15%. Given Castle Biosciences' higher possible upside, analysts clearly believe Castle Biosciences is more favorable than DermTech.

Volatility and Risk

Castle Biosciences has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, DermTech has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Institutional & Insider Ownership

66.4% of Castle Biosciences shares are owned by institutional investors. Comparatively, 51.4% of DermTech shares are owned by institutional investors. 39.7% of Castle Biosciences shares are owned by insiders. Comparatively, 16.5% of DermTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Castle Biosciences beats DermTech on 9 of the 13 factors compared between the two stocks.